Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Osteosarcoma | Research

Construction of a prognostic risk score model based on the ARHGAP family to predict the survival of osteosarcoma

Authors: Wenda Liu, Kezhou Xia, Di Zheng, Xinghan Huang, Zhun Wei, Zicheng Wei, Weichun Guo

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Osteosarcoma (OS) is the most common primary malignancy of bone tumors. More and more ARHGAP family genes have been confirmed are to the occurrence, development, and invasion of tumors. However, its significance in osteosarcoma remains unclear. In this study, we aimed to identify the relationship between ARHGAP family genes and prognosis in patients with OS.

Methods

OS samples were retrieved from the TCGA and GEO databases. We then performed LASSO regression analysis and multivariate COX regression analysis to select ARHGAP family genes to construct a risk prognosis model. We then validated this prognostic model. We utilized ESTIMATE and CIBERSORT algorithms to calculate the stroma and immune scores of samples, as well as the proportions of tumor infiltrating immune cells (TICs). Finally, we conducted in vivo and in vitro experiments to investigate the effect of ARHGAP28 on osteosarcoma.

Results

We selected five genes to construct a risk prognosis model. Patients were divided into high- and low-risk groups and the survival time of the high-risk group was lower than that of the low-risk group. The high-risk group in the prognosis model constructed had relatively poor immune function. GSEA and ssGSEA showed that the low-risk group had abundant immune pathway infiltration. The overexpression of ARHGAP28 can inhibit the proliferation, migration, and invasion of osteosarcoma cells and tumor growth in mice, and IHC showed that overexpression of ARHGAP28 could inhibit the proliferation of tumor cells.

Conclusion

We constructed a risk prognostic model based on five ARHGAP family genes, which can predict the overall survival of patients with osteosarcoma, to better assist us in clinical decision-making and individualized treatment.
Appendix
Available only for authorised users
Literature
1.
Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med. 2021;385:2066–76.PubMedCrossRef
2.
Jiang ZY, Liu JB, Wang XF, Ma YS, Fu D. Current Status and Prospects of Clinical Treatment of Osteosarcoma. Technol Cancer Res Treat. 2022;21:15330338221124696.PubMedPubMedCentralCrossRef
3.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.PubMedCrossRef
4.
L. Kager, A. Zoubek, U. Potschger, U. Kastner, S. Flege, B. Kempf-Bielack, D. Branscheid, R. Kotz, M. Salzer-Kuntschik, W. Winkelmann, G. Jundt, H. Kabisch, P. Reichardt, H. Jurgens, H. Gadner, S.S. Bielack, and G. Cooperative German-Austrian-Swiss Osteosarcoma Study, Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21 (2003) 2011–8.
5.
Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defaschelles AS, Hartmann O. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome–the French pediatric experience. Cancer. 2005;104:1100–9.PubMedCrossRef
6.
Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18:39–50.PubMedCrossRef
7.
Wu PK, Chen WM, Chen CF, Lee OK, Haung CK, Chen TH. Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol. 2009;39:514–22.PubMedCrossRef
8.
9.
Etienne-Manneville S, Hall A. Rho GTPases in cell biology Nature. 2002;420:629–35.PubMed
10.
Jansen S, Gosens R, Wieland T, Schmidt M. Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharmacol Ther. 2018;183:1–21.PubMedCrossRef
11.
Tcherkezian J, Lamarche-Vane N. Current knowledge of the large RhoGAP family of proteins. Biol Cell. 2007;99:67–86.PubMedCrossRef
12.
Kagawa Y, Matsumoto S, Kamioka Y, Mimori K, Naito Y, Ishii T, Okuzaki D, Nishida N, Maeda S, Naito A, Kikuta J, Nishikawa K, Nishimura J, Haraguchi N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Ishii H, Doki Y, Matsuda M, Kikuchi A, Mori M, Ishii M. Cell cycle-dependent Rho GTPase activity dynamically regulates cancer cell motility and invasion in vivo. PLoS ONE. 2013;8:e83629.PubMedPubMedCentralCrossRef
13.
Qiao Y, Chen J, Lim YB, Finch-Edmondson ML, Seshachalam VP, Qin L, Jiang T, Low BC, Singh H, Lim CT, Sudol M. YAP Regulates Actin Dynamics through ARHGAP29 and Promotes Metastasis. Cell Rep. 2017;19:1495–502.PubMedCrossRef
14.
Huang WK, Chen Y, Su H, Chen TY, Gao J, Liu Y, Yeh CN, Li S. ARHGAP25 Inhibits Pancreatic Adenocarcinoma Growth by Suppressing Glycolysis via AKT/mTOR Pathway. Int J Biol Sci. 2021;17:1808–20.PubMedPubMedCentralCrossRef
15.
16.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587–92.PubMedCrossRef
17.
18.
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–7.PubMedPubMedCentralCrossRef
19.
Pan Q, Wang L, Chai S, Zhang H, Li B. The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases. J Cancer. 2020;11:3207–15.PubMedPubMedCentralCrossRef
20.
Zheng D, Wei Z, Guo W. Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma. Front Genet. 2022;13:849789.PubMedPubMedCentralCrossRef
21.
Mirabello L, Troisi RJ, Savage SA, Osteosarcoma incidence and survival rates from,. to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 1973;115(2009):1531–43.
22.
Tomoda R, Seto M, Hioki Y, Sonoda J, Matsumine A, Kusuzaki K, Uchida A. Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma. Clin Exp Metastasis. 2005;22:559–64.PubMedCrossRef
23.
24.
25.
Li JP, Liu Y, Yin YH. ARHGAP1 overexpression inhibits proliferation, migration and invasion of C-33A and SiHa cell lines. Onco Targets Ther. 2017;10:691–701.PubMedPubMedCentralCrossRef
26.
Satterfield L, Shuck R, Kurenbekova L, Allen-Rhoades W, Edwards D, Huang S, Rajapakshe K, Coarfa C, Donehower LA, Yustein JT. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma. Int J Cancer. 2017;141:2062–75.PubMedPubMedCentralCrossRef
27.
Dong L, Chen F, Fan Y, Long J. MiR-34b-5p inhibits cell proliferation, migration and invasion through targeting ARHGAP1 in breast cancer. Am J Transl Res. 2020;12:269–80.PubMedPubMedCentral
28.
Qi L, Sun B, Yang B, Lu S. circRNA RPPH1 Facilitates the Aggravation of Breast Cancer Development by Regulating miR-542-3p/ARHGAP1 Pathway. Cancer Biother Radiopharm. 2022;37:708–19.PubMed
29.
Yang C, Zhang G, Zhang Y, Zhang S, Li J, Liu Y. Exosome miR-134-5p restrains breast cancer progression via regulating PI3K/AKT pathway by targeting ARHGAP1. J Obstet Gynaecol Res. 2021;47:4037–48.PubMedCrossRef
30.
Hashimoto K, Ochi H, Sunamura S, Kosaka N, Mabuchi Y, Fukuda T, Yao K, Kanda H, Ae K, Okawa A, Akazawa C, Ochiya T, Futakuchi M, Takeda S, Sato S. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc Natl Acad Sci U S A. 2018;115:2204–9.PubMedPubMedCentralCrossRef
31.
Johnstone CN, Castellvi-Bel S, Chang LM, Bessa X, Nakagawa H, Harada H, Sung RK, Pique JM, Castells A, Rustgi AK. ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene. 2004;336:59–71.PubMedCrossRef
32.
Yang C, Wu S, Mou Z, Zhou Q, Zhang Z, Chen Y, Ou Y, Chen X, Dai X, Xu C, Liu N, Jiang H. Transcriptomic Analysis Identified ARHGAP Family as a Novel Biomarker Associated With Tumor-Promoting Immune Infiltration and Nanomechanical Characteristics in Bladder Cancer. Front Cell Dev Biol. 2021;9:657219.PubMedPubMedCentralCrossRef
33.
Carbajo-Garcia MC, Corachan A, Juarez-Barber E, Monleon J, Paya V, Trelis A, Quinonero A, Pellicer A, Ferrero H. Integrative analysis of the DNA methylome and transcriptome in uterine leiomyoma shows altered regulation of genes involved in metabolism, proliferation, extracellular matrix, and vesicles. J Pathol. 2022;257:663–73.PubMedCrossRef
34.
35.
Li Y, Zeng B, Li Y, Zhang C, Ren G. Downregulated expression of ARHGAP10 correlates with advanced stage and high Ki-67 index in breast cancer. PeerJ. 2019;7:e7431.PubMedPubMedCentralCrossRef
36.
Liu L, Xie D, Xie H, Huang W, Zhang J, Jin W, Jiang W, Xie D. ARHGAP10 Inhibits the Proliferation and Metastasis of CRC Cells via Blocking the Activity of RhoA/AKT Signaling Pathway. Onco Targets Ther. 2019;12:11507–16.PubMedPubMedCentralCrossRef
37.
Luo N, Guo J, Chen L, Yang W, Qu X, Cheng Z. ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells. Cell Death Dis. 2016;7:e2157.PubMedPubMedCentralCrossRef
38.
Teng JP, Yang ZY, Zhu YM, Ni D, Zhu ZJ, Li XQ. The roles of ARHGAP10 in the proliferation, migration and invasion of lung cancer cells. Oncol Lett. 2017;14:4613–8.PubMedPubMedCentralCrossRef
39.
Fang K, Chen X, Qiu F, Xu J, Xiong H, Zhang Z. Serum-Derived Exosomes-Mediated Circular RNA ARHGAP10 Modulates the Progression of Non-Small Cell Lung Cancer Through the miR-638/FAM83F Axis. Cancer Biother Radiopharm. 2022;37:96–110.PubMed
40.
Jin M, Shi C, Yang C, Liu J, Huang G. Upregulated circRNA ARHGAP10 Predicts an Unfavorable Prognosis in NSCLC through Regulation of the miR-150-5p/GLUT-1 Axis. Mol Ther Nucleic Acids. 2019;18:219–31.PubMedPubMedCentralCrossRef
41.
Wang Z, Yao L, Li Y, Hao B, Wang M, Wang J, Gu W, Zhan H, Liu G, Wu Q. miR-337-3p inhibits gastric tumor metastasis by targeting ARHGAP10. Mol Med Rep. 2020;21:705–19.PubMed
42.
Shi F, Wu J, Jia Q, Li K, Li W, Shi Y, Wang Y, Wu S. Relationship between the expression of ARHGAP25 and RhoA in non-small cell lung cancer and vasculogenic mimicry. BMC Pulm Med. 2022;22:377.PubMedPubMedCentralCrossRef
43.
Tao L, Gu Y, Zheng J, Yang J, Zhu Y. Weichang’an suppressed migration and invasion of HCT116 cells by inhibiting Wnt/beta-catenin pathway while upregulating ARHGAP25. Biotechnol Appl Biochem. 2019;66:787–93.PubMedCrossRef
44.
Tao L, Zhu Y, Gu Y, Zheng J, Yang J. ARHGAP25: A negative regulator of colorectal cancer (CRC) metastasis via the Wnt/beta-catenin pathway. Eur J Pharmacol. 2019;858:172476.PubMedCrossRef
45.
46.
Zhang Y, Lin Y, Zhu Y, Zhang X, Tao L, Yang M. ARHGAP25 expression in colorectal cancer as a biomarker associated with favorable prognosis. Mol Clin Oncol. 2022;16:84.PubMedPubMedCentralCrossRef
47.
Boesch M, Spizzo G, Seeber A. Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition. Stem Cells Transl Med. 2018;7:495–501.PubMedPubMedCentralCrossRef
48.
Wang W, Li Q, Yang T, Li D, Ding F, Sun H, Bai G. Anti-cancer effect of Aquaporin 5 silencing in colorectal cancer cells in association with inhibition of Wnt/beta-catenin pathway. Cytotechnology. 2018;70:615–24.PubMedPubMedCentralCrossRef
49.
Ding FP, Tian JY, Wu J, Han DF, Zhao D. Identification of key genes as predictive biomarkers for osteosarcoma metastasis using translational bioinformatics. Cancer Cell Int. 2021;21:640.PubMedPubMedCentralCrossRef
50.
Lettieri CK, Appel N, Labban N, Lussier DM, Blattman JN, Hingorani P. Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy. 2016;8:1233–44.PubMedCrossRef
51.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.PubMedPubMedCentralCrossRef
52.
53.
54.
Metadata
Title
Construction of a prognostic risk score model based on the ARHGAP family to predict the survival of osteosarcoma
Authors
Wenda Liu
Kezhou Xia
Di Zheng
Xinghan Huang
Zhun Wei
Zicheng Wei
Weichun Guo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11673-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Elemental profiles in distant tissues during tumor progression

Research

Advanced Ann Arbor stage and age over 60 years as prognostic predictors in patients with primary cervical lymphoma: a retrospective cohort study and systematic review

Research

Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity

Research

PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis

Research

Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma

Research

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits